

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5: <b>C07K 1/02, 1/04, 7/06, 7/10, 7/64, C12P 21/02, A61K 37/02</b>		<b>A1</b>	(11) International Publication Number: <b>WO 94/14836</b>
			(43) International Publication Date: <b>7 July 1994 (07.07.94)</b>
(21) International Application Number: <b>PCT/US93/12110</b>		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: <b>13 December 1993 (13.12.93)</b>		Published <i>With international search report.</i>	
(30) Priority Data: <b>997,771 18 December 1992 (18.12.92) US</b>			
(60) Parent Application or Grant (63) Related by Continuation <b>US 997,771 (CIP) Filed on 18 December 1992 (18.12.92)</b>			
(71) Applicant (for all designated States except US): <b>CENTOCOR, INC. [US/US]; 200 Great Valley Parkway, Malvern, PA 19355-1307 (US).</b>			
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>HEAVNER, George, A. [US/US]; 6 Oak Glen Drive, Malvern, PA 19355 (US). KRUSZYNSKI, Marian [PL/US]; 1100 West Chester Pike, Apartment E20, West Chester, PA 19383 (US).</b>			
(74) Agent: <b>ELDERKIN, Dianne, B.; Woodcock Washburn Kurtz Mackiewicz &amp; Norris, One Liberty Place, 46th floor, Philadelphia, PA 19103 (US).</b>			

(54) Title: PEPTIDE INHIBITORS OF SELECTIN BINDING

(57) Abstract

The present invention provides novel peptides having as their core region portions of the 109-118 amino acid sequence of P-selectin, E-selectin or L-selectin. The invention also provides pharmaceutical compositions comprising the peptides of the invention, and diagnostic and therapeutic methods utilizing the peptides and pharmaceutical compositions of the invention.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

## PEPTIDE INHIBITORS OF SELECTIN BINDING

### Background of the Invention

This invention relates to peptides which inhibit binding of selectins such as P-selectin, E-selectin and L-selectin.

The adherence of platelets and leukocytes to vascular surfaces is a critical component of the inflammatory response and is part of a complex series of reactions involving the simultaneous and interrelated activation of the complement, coagulation, and immune systems.

The complement proteins collectively play a leading role in the immune system, both in the identification and in the removal of foreign substances and immune complexes, as reviewed by Muller-Eberhard, H.J., Ann. Rev. Biochem. 57: 15 321-347 (1988). Central to the complement system are the C3 and C4 proteins, which when activated covalently attach to nearby targets, marking them for clearance. In order to help control this process, a remarkable family of soluble and membrane-bound regulatory proteins has evolved, each of which 20 interacts with activated C3 and/or C4 derivatives. The coagulation and inflammatory pathways are regulated in a coordinate fashion in response to tissue damage. For example, in addition to becoming adhesive for leukocytes, activated endothelial cells express tissue factor on the cell 25 surface and decrease their surface expression of thrombomodulin, leading to a net facilitation of coagulation reactions on the cell surface. In some cases, a single

- 2 -

receptor can be involved in both inflammatory and coagulation processes.

Leukocyte adherence to vascular endothelium is a key initial step in migration of leukocytes to tissues in 5 response to microbial invasion. Although a class of inducible leukocyte receptors, the CD11-CD18 molecules, are thought to have some role in adherence to endothelium, mechanisms of equal or even greater importance for leukocyte adherence appear to be due to inducible changes in the 10 endothelium itself.

Activated platelets have also been shown to interact with both neutrophils and monocytes *in vitro*. The interaction of platelets with monocytes may be mediated in part by the binding of thrombospondin to platelets and 15 monocytes, although other mechanisms have not been excluded. The mechanisms for the binding of neutrophils to activated platelets are not well understood, except that it is known that divalent cations are required. In response to vascular injury, platelets are known to adhere to subendothelial 20 surfaces, become activated, and support coagulation. Platelets and other cells may also play an important role in the recruitment of leukocytes into the wound in order to contain microbial invasion.

Endothelium exposed to "rapid" activators such as 25 thrombin and histamine becomes adhesive for neutrophils within two to ten minutes, while endothelium exposed to cytokines such as tumor necrosis factor and interleukin-1 becomes adhesive after one to six hours. The rapid endothelial-dependent leukocyte adhesion has been associated 30 with expression of the lipid mediator platelet activating factor (PAF) on the cell surface, and presumably, the appearance of other endothelial surface receptors. The slower cytokine-inducible endothelial adhesion for leukocytes is mediated, at least in part, by E-selectin that is 35 synthesized by endothelial cells after exposure to cytokines and then transported to the cell surface, where it binds neutrophils. The isolation, characterization and cloning of

- 3 -

E-selectin or ELAM-1 is reviewed by Bevilacqua, et al., in Science 243, 1160-1165 (1989). L-selectin, a peripheral lymph node homing receptor, also called "the murine Mel 14 antigen", "Leu 8", the "Leu 8 antigen" and "LAM-1", is 5 another structure on neutrophils, monocytes, and lymphocytes that binds lymphocytes to high endothelial venules in peripheral lymph nodes. The characterization and cloning of the protein is reviewed by Lasky, et al., Cell 56, 1045-1055 (1989) (mouse) and Tedder, et al., J. Exp. Med. 170, 123-133 10 (1989).

P-selectin, also known as GMP-140 (granule membrane protein 140), or PADGEM, is a cysteine-rich and heavily glycosylated integral membrane glycoprotein with an apparent molecular weight of 140,000 as assessed by sodium dodecyl 15 sulfate polyacrylamide gel electrophoresis (SDS-PAGE). P-selectin was first purified from human platelets by McEver and Martin, J. Biol. Chem. 259: 9799-9804 (1984). The protein is present in alpha granules of resting platelets but is rapidly redistributed to the plasma membrane following 20 platelet activation, as reported by Stenberg, et al., (1985). The presence of P-selectin in endothelial cells and its biosynthesis by these cells was reported by McEver, et al., Blood 70(5) Suppl. 1:355a, Abstract No. 1274 (1987). In endothelial cells, P-selectin is found in storage granules 25 known as the Weibel-Palade bodies. (McEver, et al. J. Clin. Invest. 84: 92-99 (1989) and Hattori, et al., J. Biol. Chem. 264: 7768-7771 (1989)). P-selectin (called GMP-140 or PADGEM) has also been reported to mediate the interaction of activated platelets with neutrophils and monocytes by Larsen, 30 et al., in Cell 59, 305-312 (October 1989) and Hamburger and McEver, Blood 75: 550-554 (1990).

The cDNA-derived amino acid sequence, reported by Johnston, et al., in Cell 56, 1033-1044 (March 24 1989), and in U.S. Serial No. 07/320,408 filed March 8, 1989, indicates 35 that it contains a number of modular domains that are likely to fold independently. Beginning at the N-terminus, these include a "lectin" domain, an "EGF" domain, nine tandem

- 4 -

consensus repeats similar to those in complement binding proteins, a transmembrane domain (except in a soluble form that appears to result from differential splicing), and a cytoplasmic tail.

5 When platelets or endothelial cells are activated by mediators such as thrombin, the membranes of the storage granules fuse with the plasma membrane, the soluble contents of the granules are released to the external environment, and membrane bound P-selectin is presented within seconds on the  
10 cell surface. The rapid redistribution of P-selectin to the surface of platelets and endothelial cells as a result of activation suggested that this glycoprotein could play an important role at sites of inflammation or vascular disruption.

15 This important role has been confirmed by the observation that P-selectin is a receptor for neutrophils (Geng et al., Nature 343:757-760 (1990); Hamburger and McEver, Blood 75:550-554 (1990)), monocytes (Larsen, et al. Cell 59:305-312 (1989)); Moore, et al., J. Cell Biol. 112:491-499 (1991)), and perhaps a subset of lymphocytes (Moore, et al. J. Cell Biol. 112:491-499 (1991)). Thus, GMP-140 can serve as a receptor for leukocytes following its rapid mobilization to the surfaces of platelets and endothelial cells stimulated with agonists such as thrombin.  
20  
25 This role in leukocyte recruitment may be important in hemostatic and inflammatory processes in both physiologic and pathologic states.

Peptides derived from P-selectin are described in U.S. Serial No. 07/554,199 entitled "Functionally Active  
30 Selectin-Derived Peptides" filed July 17, 1990 by Rodger P. McEver that are useful in diagnostics and in modulating the hemostatic and inflammatory responses in a patient wherein a therapeutically effective amount of a peptide capable of blocking leukocyte recognition of P-selectin is administered  
35 to the patient. U.S. Serial No. 07/554,199 filed July 17, 1990, also discloses that peptide sequences within the lectin domain of P-selectin, having homology with the lectin domains

- 5 -

of other proteins, especially E-selectin and the L-selectin, selectively inhibit neutrophil adhesion to purified P-selectin, and can therefore be used in diagnostic assays of patients and diseases characterized by altered binding by 5 these molecules, in screening assays for compounds altering this binding, and in clinical applications to inhibit or modulate interactions of leukocytes with platelets or endothelial cells involving coagulation and/or inflammatory processes.

10 E-selectin, L-selectin, and P-selectin have been termed "selectins", based on their related structure and function. E-selectin is not present in unstimulated endothelium. However, when endothelium is exposed to cytokines such as tumor necrosis factor or interleukin-1, the 15 gene for E-selectin is transcribed, producing RNA which in turn is translated into protein. The result is that E-selectin is expressed on the surface of endothelial cells one to four hours after exposure to cytokines, as reported by Bevilacqua et al., Proc.Natl.Acad.Sci.USA 84: 9238-9242 20 (1987) (in contrast to P-selectin, which is stored in granules and presented on the cell surface within seconds after activation). E-selectin has been shown to mediate the adherence of neutrophils to cytokine-treated endothelium and thus appears to be important in allowing leukocytes to 25 migrate across cytokine-stimulated endothelium into tissues. The cDNA-derived primary structure of E-selectin indicates that it contains a "lectin" domain, an EGF domain, and six (instead of the nine in P-selectin) repeats similar to those of complement-regulatory proteins, a transmembrane domain, 30 and a short cytoplasmic tail. There is extensive sequence homology between P-selectin and E-selectin throughout both proteins, but the similarity is particularly striking in the lectin and EGF domains.

Homing receptors are lymphocyte surface structures 35 that allow lymphocytes to bind to specialized endothelial cells in lymphatic tissues, termed high endothelial cells or high endothelial venules (reviewed by Yednock and Rosen,

- 6 -

Advances in Immunology, vol. 44, F.I. Dixon, ed., 313-378 (Academic Press, New York 1989). This binding allows lymphocytes to migrate across the endothelium into the lymphatic tissues where they are exposed to processed 5 antigens. The lymphocytes then re-enter the blood through the lymphatic system. L-selectin, a lymphocyte homing receptor, contains a lectin domain, an EGF domain, two complement-binding repeats, a transmembrane domain, and a short cytoplasmic tail. L-selectin also shares extensive 10 sequence homology with P-selectin, particularly in the lectin and EGF domains.

Based on a comparison of the lectin domains between P-selectin, E-selectin, and L-selectin, it may be possible to select those peptides inhibiting binding of neutrophils to P- 15 selectin which will inhibit binding of E-selectin, L-selectin, and other homologous selectins, to components of the inflammatory process, or, conversely, which will inhibit only P-selectin binding.

The *in vivo* significance of platelet-leukocyte 20 interactions has not been studied carefully. However, in response to vascular injury, platelets are known to adhere to subendothelial surfaces, become activated, and support coagulation. Platelets and other cells may also play an 25 important role in the recruitment of leukocytes into the wound in order to contain microbial invasion. Conversely, leukocytes may recruit platelets into tissues at sites of inflammation, as reported by Issekutz, et al., Lab. Invest. 49:716 (1983).

The coagulation and inflammatory pathways are 30 regulated in a coordinate fashion in response to tissue damage. For example, in addition to becoming adhesive for leukocytes, activated endothelial cells express tissue factor on the cell surface and decrease their surface expression of thrombomodulin, leading to a net facilitation of coagulation 35 reactions on the cell surface. In some cases, a single receptor can be involved in both inflammatory and coagulation processes.

- 7 -

Proteins involved in the hemostatic and inflammatory pathways are of interest for diagnostic purposes and treatment of human disorders. However, there are many problems using proteins therapeutically. Proteins are 5 usually expensive to produce in quantities sufficient for administration to a patient. Moreover, there can be a reaction against the protein after it has been administered more than once to the patient. It is therefore desirable to develop peptides having the same, or better, activity as the 10 protein, which are inexpensive to synthesize, reproducible and relatively innocuous.

It is preferable to develop peptides which can be prepared synthetically, having activity at least equal to, or greater than, the peptides derived from the protein itself.

15 It is therefore an object of the present invention to provide peptides interacting with cells recognized by selectins, including P-selectin, E-selectin, and L-selectin.



It is another object of the present invention to provide methods for using these peptides to inhibit leukocyte 20 adhesion to endothelium or to platelets.

It is a further object of the present invention to provide methods for using these peptides to modulate the immune response and the hemostatic pathway.

It is yet another object of the present invention 25 to provide peptides for use in diagnostic assays relating to P-selectin, E-selectin and L-selectin.

#### Summary of the Invention

This invention relates to novel peptides having as their core region portions of the 109-118 amino acid sequence 30 of P-selectin, E-selectin or L-selectin. More specifically, this invention relates to novel peptides of Formulas I and II:



- 8 -

or pharmaceutically acceptable salts thereof, wherein:

X' is an N-terminus amino acid linear sequence of from zero to 10 amino acids, and R<sup>1</sup> is a moiety attached to the terminal  $\alpha$  amino group of X', or the terminal  $\alpha$ -amino group of the adjacent amino acid if X is zero;

X" is a C-terminus amino acid linear sequence of from zero to 10 amino acids, and R<sup>2</sup> is a moiety attached to the carboxyl carbon of X" or the carboxyl carbon of the adjacent amino acid if X" is zero;

10 A' is null (signifying no amino acid) or D- or L-cysteine;

A" is D- or L-cysteine;

15 B' is D- or L-histidine, D- or L-serine, D- or L-leucine, D- or L-phenylalanine, D- or L-asparagine, D- or L-proline or D- or L-glutamine;

C' is D- or L-lysine, D- or L-histidine, D- or L-arginine, or D- or L-serine;

20 D' is D- or L-lysine, D- or L-leucine, D- or L-alanine, D- or L-phenylalanine, D- or L-histidine, D- or L-arginine, or D- or L-serine;

E' is D- or L-lysine, D- or L-phenylalanine, D- or L-glutamine, or D- or L-arginine;

25 F' is D- or L-histidine, D- or L-leucine, D- or L-alanine, D- or L-isoleucine, D- or L-threonine, or D- or L-arginine;

G' is D- or L-alanine, D- or L-phenylalanine, D- or L-histidine, D- or L-isoleucine, or D- or L-glutamine;

H' is D- or L-leucine, D- or L-phenylalanine, D- or L-isoleucine, D- or L-proline, or D- or L-alanine;

30 I' is D- or L-cysteine, D- or L-phenylalanine, D- or L-isoleucine, D- or L-histidine, D- or L-leucine, D- or L-valine, D- or L-threonine, or D- or L-serine;

I" is D- or L-cysteine;

35 J' is D- or L-tyrosine, D- or L-phenylalanine, D- or L-isoleucine, or D- or L-valine;

- 9 -

$R^1$  is hydrogen (signifying a free N-terminal group), lower alkyl, aryl, formyl, alkanoyl, aroyl, alkyloxycarbonyl or aryloxycarbonyl;

$R^2$  is OH (signifying a free C-terminal carboxylic acid),  $OR^3$ , signifying ester, where  $R^3$  is lower alkyl or aryl or  $R^2$  is  $NR^5R^6$  where  $R^5$  and  $R^6$  are each selected independently from hydrogen, lower alkyl, aryl or cyclic alkyl.

The peptides of Formulas I and II have as their core region the 109-118 amino acid sequence of the selectins.

10 Residue 1 is defined as the N-terminus of the mature protein after the cleavage of the signal peptide.

The peptides of Formulas I and II should inhibit the binding of neutrophils to P-selectin in concentrations of peptide ranging from about 10 to about 1500  $\mu$ M. Tests also 15 indicate that alterations within the core sequence, as well as N-terminal and C-terminal flanking regions, do not result in loss of biological activity.

This invention relates not only to the novel peptides of Formulas I and II, but also to pharmaceutical 20 compositions comprising them, to diagnostic and therapeutic methods utilizing them, and to methods of preparing them.

#### Detailed Description of the Invention

Preferred peptides of this invention are those of Formula I and II wherein, together or independently:  $R^1$  is 25 hydrogen or acetyl (Ac) and  $R^2$  is OH or  $NH_2$ . More preferred are those peptides wherein  $R^2$  is  $NH_2$ .

One group of preferred peptides includes those of Formula I where, independently,  $A'$  is null,  $B'$  is Phe, His, Leu, Asn or Ser;  $C'$  is Lys or Arg;  $D'$  is Lys, Phe, Leu, Ala; 30  $E'$  is Lys or Arg;  $F'$  is Leu or Arg;  $G'$  is Ala;  $H'$  is Leu;  $I'$  is Cys, Ile or Phe, and  $J'$  is Tyr.

Test results have indicated that peptides in which  $E'$  is Arg have superior activity. Accordingly, a more preferred group of peptides are those in which  $E'$  is Arg.

35 Specifically preferred peptides include the following:

- 10 -

(SEQ ID NO:1) Cys-Leu-Lys-Lys-Lys-His-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:2) Cys-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

5 (SEQ ID NO:3) Cys-His-Lys-Leu-Lys-Ala-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:4) cyclo-(Cys-Leu-Lys-Lys-Lys-His-Ala-Leu-Cys)-Tyr-NH<sub>2</sub>;

10 (SEQ ID NO:5) cyclo-(Cys-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys)-Tyr-NH<sub>2</sub>;

(SEQ ID NO:6) cyclo-(Cys-His-Lys-Leu-Lys-Ala-Ala-Leu-Cys)-Tyr-NH<sub>2</sub>;

(SEQ ID NO:7) Ac-Phe-Lys-Lys-Lys-Leu-Ala-Ley-Cys-Tyr-NH<sub>2</sub>;

15 (SEQ ID NO:8) Phe-Lys-Lys-Lys-Leu-Ala-Ley-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:9) Ac-His-Lys-Lys-Lys-Leu-Ala-Ley-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:10) His-Lys-Lys-Lys-Leu-Ala-Ley-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:11) Leu-Lys-Lys-His-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

20 (SEQ ID NO:12) Ac-Leu-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:13) Leu-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:14) Ac-Asn-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

25 (SEQ ID NO:15) Asn-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:16) Pro-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:17) Gln-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:18) Ser-His-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

30 (SEQ ID NO:19) Ac-Ser-Lys-Ala-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:20) Ser-Lys-Phe-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:21) Ser-Lys-His-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:22) Ser-Lys-Lys-Phe-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

35 (SEQ ID NO:23) Ac-Ser-Lys-Lys-Lys-Ala-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

- 11 -

(SEQ ID NO:24) Ser-Lys-Lys-Lys-Ala-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:25) Ser-Lys-Lys-Lys-His-ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:26) Ser-Lys-Lys-Lys-Ile-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:27) Ser-Lys-Lys-Lys-Leu-Ala-Phe-Cys-Tyr-NH<sub>2</sub>;  
5 (SEQ ID NO:28) Ser-Lys-Lys-Lys-Leu-Ala-Ile-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:29) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Phe-NH<sub>2</sub>;  
(SEQ ID NO:30) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Ile-NH<sub>2</sub>;  
(SEQ ID NO:31) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:32) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Phe-Tyr-NH<sub>2</sub>;  
10 (SEQ ID NO:33) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Ile-Val-NH<sub>2</sub>;  
(SEQ ID NO:34) Ac-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Ile-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:35) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Ile-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:36) Ser-Lys-Lys-Lys-Leu-Ala-Leu-His-Tyr-NH<sub>2</sub>;  
15 (SEQ ID NO:37) Ac-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Leu-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:38) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Leu-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:39) Ac-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Val-Tyr-NH<sub>2</sub>;  
20 (SEQ ID NO:40) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Val-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:41) Ser-Lys-Lys-Lys-Leu-Ala-Ley-Thr-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:42) Ser-Lys-Lys-Lys-Leu-Ala-Pro-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:43) Ser-Lys-Lys-Lys-Leu-Phe-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:44) Ser-Lys-Lys-Lys-Leu-His-Leu-Cys-Tyr-NH<sub>2</sub>;  
25 (SEQ ID NO:45) Ser-Lys-Lys-Lys-Leu-Ile-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:46) Ser-Lys-Lys-Lys-Leu-Gln-Ala-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:47) Ac-Ser-Lys-Lys-Lys-thr-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:48) Ser-Lys-Lys-Gln-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
30 (SEQ ID NO:49) Ac-Ser-Lys-Lys-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

- 12 -

	(SEQ ID NO:50)	Ser-Lys-Lys-Arg-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:51)	Ac-Ser-Lys-Leu-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:52)	Ser-Lys-Leu-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
5	(SEQ ID NO:53)	Ac-Ser-Lys-Arg-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:54)	Ser-Lys-Arg-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:55)	Ac-Ser-Lys-Arg-Lys-Arg-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
10	(SEQ ID NO:56)	Ser-Lys-Arg-Lys-Arg-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:57)	Ac-Ser-Lys-Arg-Arg-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:58)	Ser-Lys-Arg-Arg-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:59)	Ser-Lys-Arg-Arg-Leu-Ala-Leu-Ser-Tyr-NH <sub>2</sub> ;
15	(SEQ ID NO:60)	Ser-Lys-Ser-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:61)	Ac-Ser-Arg-Ala-Arg-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:62)	Ser-Arg-Ala-Arg-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
20	(SEQ ID NO:63)	Ac-Ser-Arg-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:64)	Ser-Arg-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:65)	Ac-Ser-Arg-Lys-Arg-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:66)	Ser-Arg-Lys-Arg-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
25	(SEQ ID NO:67)	Ser-Arg-Lys-Arg-Leu-Ala-Leu-Ser-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:68)	Ac-Ser-Arg-Arg-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:69)	Ser-Arg-Arg-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;
	(SEQ ID NO:70)	Ser-Ser-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH <sub>2</sub> ;

30 More preferred peptides are those with Sequence ID Nos. 2, 6, 8, 9, 12, 15, 20, 31, 33, 35, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 61, 62, 63, 64, 65, 66, 68, and 69.

- 13 -

As used herein, the term "alkyl" includes branched, straight-chain, and cyclic saturated hydrocarbons. The term "lower alkyl" means an alkyl having from one to six carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, 5 isobutyl, t-butyl, pentyl, isopentyl, neopentyl, cyclopentylmethyl and hexyl. The term "alkanoyl" means




10 wherein R<sup>7</sup> is a alkyl group.

The term "aroyl" means




15 wherein R<sup>8</sup> is an aryl group. The term "aryl" means an aromatic or heteroaromatic structure having between one and three rings, which may or may not be ring fused structures, and are optionally substituted with halogens, carbons, or other heteroatoms such as nitrogen (N), sulfur 20 (S), phosphorus (P), and boron (B).

The term alkoxy carbonyl means



25 wherein R<sup>9</sup> is a lower alkyl group.

The term aryloxycarbonyl means



30 wherein R<sup>10</sup> is an aryl and arylmethyl group.

Halogen refers to fluorine, chlorine, bromine or iodine.

The term "terminal  $\alpha$ -amino group of X" refers to the  $\alpha$ -amino group of the N-terminal amino acid of X.

35 The peptides of Formulas I and II can be used in the form of the free peptide or a pharmaceutically acceptable salt. Amine salts can be prepared by treating the peptide with an acid according to known methods. Suitable acids include inorganic acids such as hydrochloric acid, 40 hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids

- 14 -

such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalenesulfonic acid, and sulfanilic acid.

5       Carboxylic acid groups in the peptide can be converted to a salt by treating the peptide with a base according to known methods. Suitable bases include inorganic bases such as sodium hydroxide, ammonium hydroxide, and potassium hydroxide, and organic bases such as mono-, di-,  
10 and tri-alkyl and aryl amines (e.g., triethylamine, diisopropylamine, methylamine, and dimethylamine and optionally substituted mono-, di, and tri-ethanolamines.

As referred to herein, the amino acid components of the peptides and certain materials used in their preparation  
15 are identified by abbreviations for convenience. These abbreviations are as follows:

- 15 -

	<u>Amino Acid</u>	<u>Abbreviations</u>	
	L-alanine	Ala	A
	D-alanine	D-Ala	a
	L-arginine	Arg	R
5	D-arginine	D-Arg	r
	D-asparagine	D-Asn	n
	L-asparagine	Asn	N
	L-aspartic acid	Asp	D
	D-aspartic acid	D-Asp	d
10	L-cysteine	Cys	C
	D-cysteine	D-Cys	c
	L-glutamic acid	Glu	E
	D-glutamic acid	D-Glu	e
	L-glutamine	Gln	Q
15	D-glutamine	D-Gln	q
	glycine	Gly	G
	L-histidine	His	H
	D-histidine	D-His	h
	L-isoleucine	Ile	I
20	D-isoleucine	D-Ile	i
	L-leucine	Leu	L
	D-leucine	D-Leu	l
	L-lysine	Lys	K
	D-lysine	D-Lys	k
25	L-phenylalanine	Phe	F
	D-phenylalanine	D-Phe	f
	L-proline	Pro	P
	D-proline	D-Pro	p
	L-serine	Ser	S
30	D-serine	D-Ser	s
	L-threonine	Thr	T
	D-threonine	D-Thr	t
	L-tyrosine	Tyr	Y
	D-tyrosine	D-Tyr	y
35	L-tryptophan	Trp	W
	D-tryptophan	D-Trp	w
	L-valine	Val	V
	D-valine	D-Val	v
	L-methionine	Met	M
40	D-methionine	D-Met	m

	<u>Reagents</u>	<u>Abbreviations</u>
	Trifluoroacetic acid	TFA
	Methylene chloride	CH <sub>2</sub> Cl <sub>2</sub>
	N,N-Diisopropylethylamine	DIEA
45	N-Methylpyrrolidone	NMP
	1-Hydroxybenzotriazole	HOBT
	Dimethylsulfoxide	DMSO
	Acetic anhydride	Ac <sub>2</sub> O
	Diisopropylcarbodiimide	DIC
50	Acetic acid	HOAc

- 16 -

Amino acids preceded by L- or D- refer, respectively, to the L- or D- enantiomer of the amino acid, whereas amino acids not preceded by L- or D- refer to the L-enantiomer.

#### Methods of Preparation of Peptides

5        The peptides can generally be prepared following known techniques, as described, for example, in the cited publications, the teachings of which are specifically incorporated herein. In a preferred method, the peptides are prepared following the solid-phase synthetic technique

10      initially described by Merrifield in J.Amer.Chem.Soc., 85, 2149-2154 (1963). Other techniques may be found, for example, in M. Bodanszky, et al, Peptide Synthesis, second edition, (John Wiley & Sons, 1976), as well as in other reference works known to those skilled in the art.

15      Appropriate protective groups usable in such syntheses and their abbreviations will be found in the above text, as well as in J.F.W. McOmie, Protective Groups in Organic Chemistry, (Plenum Press, New York, 1973). The common protective groups used herein are t-butyloxycarbonyl (Boc),

20      fluorenylmethoxycarboyl (FMOC), benzyl (Bzl), tosyl (Tos), o-bromo-phenylmethoxycarbonyl (BrCBZ), phenylmethoxycarbonyl (CBZ), 2-chloro-phenylmethoxycarbonyl (2-Cl-CBZ), 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), trityl (Trt), formyl (CHO), and tertiary butyl (t-Bu).

25      General synthetic procedures for the synthesis of peptides of Formula I and II the invention by solid phase methodology are as follows:

- 17 -

**A. General Synthetic Procedures For Solid Phase Peptide Synthesis Using N<sup>α</sup>-Boc Protection**

		<u>REPETITIONS</u>	<u>TIME</u>
1.	25% TFA in CH <sub>2</sub> Cl <sub>2</sub>	1	3 min.
5 2.	50% TFA in CH <sub>2</sub> Cl <sub>2</sub>	1	16 min.
3.	CH <sub>2</sub> Cl <sub>2</sub>	5	3 min.
4.	5% DIEA in NMP	2	4 min.
5.	NMP	6	5 min.
6.	Coupling step	1	57 min.
10	a. Preformed BOC-Amino Acid- HOBT active ester in NMP		37 min.
	b. DMSO		16 min.
	c. DIEA		5 min.
7.	10% Ac <sub>2</sub> O, 5% DIEA in NMP	1	9 min.
15 8.	CH <sub>2</sub> Cl <sub>2</sub>	5	3 min.

**B. General Synthetic Procedure For Solid Phase Peptide Synthesis Using N<sup>α</sup>-FMOC Protection**

		<u>REPETITIONS</u>	<u>TIME</u>
1.	50% piperidine in DMF	1	1 min.
20 2.	50% piperidine in NMP	1	12 min.
3.	NMP	7	1 min.
4.	Coupling	1	71 min.
	Amino acid and HOBT in NMP added to the resin followed by the addition of DIC in NMP.		
25	HOBT active ester in NMP or		
5.	NMP	1	1 min.
6.	Repeat steps 4-5	1	
7.	NMP	2	1 min.

N-terminal acetylation on the deprotected N<sup>α</sup>-amino group of peptides synthesized using either Boc or FMOC strategies can be accomplished with 10% Ac<sub>2</sub>O and 5% DIEA in NMP, followed by washing of the peptide resin with NMP and/or CH<sub>2</sub>Cl<sub>2</sub>.

The peptides can also be prepared using standard genetic engineering techniques known to those skilled in the art. For example, the peptide can be produced enzymatically

- 18 -

by inserting nucleic acid encoding the peptide into an expression vector, expressing the DNA, and translating the DNA into the peptide in the presence of the required amino acids. The peptide is then purified using chromatographic or 5 electrophoretic techniques, or by means of a carrier protein which can be fused to, and subsequently cleaved from, the peptide by inserting into the expression vector in phase with the peptide encoding sequence a nucleic acid sequence encoding the carrier protein. The fusion protein-peptide may 10 be isolated using chromatographic, electrophoretic or immunological techniques (such as binding to a resin via an antibody to the carrier protein). The peptide can be cleaved using chemical methodology or enzymatically, as by, for example, hydrolases.

15 Peptides of the invention can also be prepared using solution methods, by either stepwise or fragment condensations. An appropriately alpha amino-protected amino acid is coupled to an appropriately alpha carboxyl protected amino acid (such protection may not be required depending on 20 the coupling method chosen) using diimides, symmetrical or unsymmetrical anhydrides, BOP, or other coupling reagents or techniques known to those skilled in the art. These techniques may be either or enzymatic. The alpha amino and/or alpha carboxyl protecting groups are removed and the 25 next suitably protected amino acid or block of amino acids are coupled to extend the growing peptide. Various combinations of protecting groups and of chemical and/or enzymatic techniques and assembly strategies can be used in each synthesis.

30 The peptides of Formula II are cyclic by virtue of the formation of a disulfide bond between cysteine residues. The general techniques for the formation of this bond are described by G. Barany and R. B. Merrifield in The Peptides Analysis, Synthesis, Biology, (Academic Press, Inc., 1979), 35 as well as in other reference works known to those skilled in the art.

**Methods of Preparation of Pharmaceutical Compositions**

Pharmaceutical compositions of this invention comprise a pharmaceutically acceptable carrier or diluent and an effective quantity of one or more of the peptides of Formula 5 I or II or an acid or base salt thereof. The carrier or diluent may take a wide variety of forms depending on the form of preparation desired for administration, e.g., sublingual, rectal, nasal, oral, or parenteral.

In preparing the compositions in oral dosage form, any 10 of the usual pharmaceutical media may be employed, for example, waters, oils, alcohols, flavoring agents, preservatives, and coloring agents, to make an oral liquid preparation (e.g., suspension, elixir, or solution) or with carriers such as starches, sugars, diluents, granulating 15 agents, lubricants, binders, and disintegrating agents, to make an oral solid preparation (e.g., powder, capsule, or tablet).

Controlled release forms or enhancers to increase bioavailability may also be used. Because of their ease in 20 administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.

For parenteral products, the carrier will usually be 25 sterile water, although other ingredients to aid solubility or as preservatives may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers and suspending agents can be employed.

The peptides can also be administered locally at a 30 wound or inflammatory site by topical application of a solution or cream.

Alternatively, the peptide may be administered in liposomes or microspheres (or microparticles). Methods for preparing liposomes and microspheres for administration to a 35 patient are known to those skilled in the art. U.S. Patent No. 4,789,734 describes methods for encapsulating biological materials in liposomes. Essentially, the material is

- 20 -

dissolved in an aqueous solution, the appropriate phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary. A review of known methods is by G. Gregoriadis, 5 Chapter 14, "Liposomes", Drug Carriers in Biology and Medicine, pp. 287-341 (Academic Press, 1979). Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the bloodstream. 10 Alternatively, the peptide can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time, ranging from days to months. See, for example, U.S. Patents Nos. 4,906,474, 4,925,673 and 3,625,214.

15 The peptides are generally active when administered parenterally in amounts of at least about 1  $\mu$ g/kg body weight. Effective doses by other routes of administration are generally those which result in similar blood level to i.v. doses of at least about 1  $\mu$ g/Kg. For treatment to 20 prevent organ injury in cases involving reperfusion, the peptides may be administered parenterally in amounts from about 0.01 to about 10 mg/kg body weight. Generally, the same range of dosage amounts may be used in treatment of other diseases or of conditions where inflammation is to be 25 reduced. This dosage will be dependent, in part, on whether one or more peptides are administered. A synergistic effect may be seen with combinations of peptides from different, or overlapping, regions of the lectin domain, or in combination with peptides derived from the EGF domain of P-, E- or L- 30 selectin. For treatment to prevent organ injury in cases involving reperfusion, the peptides may be administered parenterally in amounts from about 0.01 to about 10 mg/kg body weight. Generally, the same range of dosage amounts may be used in treatment of other diseases or of conditions where 35 inflammation is to be reduced. This dosage will be dependent, in part, on whether one or more peptides are administered. A synergistic effect may be seen with

- 21 -

combinations of peptides from different, or overlapping, regions of the lectin domain, or in combination with peptides derived from the EGF domain of P-selectin.

#### Methods for Demonstrating Binding

5 Peptides that are biologically active are those which inhibit binding of neutrophils, monocytes, subsets of lymphocytes or other cells to P-selectin, or which inhibit leukocyte adhesion to endothelium that is mediated by ELAM-1 and/or the homing receptor.

10 Peptides can be screened for their ability to inhibit adhesion to cells, for example, neutrophil adhesion to purified P-selectin immobilized on plastic wells, using the assay described by Geng, et al., Nature 343, 757-760 (1990). Human neutrophils are isolated from heparinized whole

15 blood by density gradient centrifugation on Mono-Poly resolving media, Flow Laboratories. Neutrophil suspensions are greater than 98% pure and greater than 95% viable by trypan blue exclusion. For adhesion assays, neutrophils are suspended at a concentration of  $2 \times 10^6$  cells/mL in Hanks' balanced salt solution containing 1.26 mM Ca<sup>2+</sup> and 0.81 mM Mg<sup>2+</sup> (HBSS, Gibco) with 5 mg/mL human serum albumin (HBSS/HSA). Adhesion assays are conducted in triplicate in 96-well microtiter plates, Corning, incubated at 4°C overnight with 50 microliters of various protein solutions.

20 P-selectin is isolated from human platelet lysates by immunoaffinity chromatography on antibody S12-Sepharose™ and ion-exchange chromatography on a Mono-Q™ column (FLPC, Pharmacia Fine Chemicals), as follows.

25 Outdated human platelet packs (100 units) obtained from a blood bank and stored at 4°C are pooled, adjusted to 5 mM EDTA at pH 7.5, centrifuged at 4,000 rpm for 30 minutes in 1 liter bottles, then washed three times with 1 liter of 0.1 M NaCl, 20 mM Tris pH 7.5 (TBS), 5 mM EDTA, 5 mM benzamidine.

30 The pellets are then resuspended in a minimum amount of wash buffer and made 1 mM in DIFP, then frozen in 50 mL

- 22 -

screwtop tubes at -80°C. The frozen platelets are thawed and resuspended in 50 mL TBS, 5 mM benzamidine, 5 mM EDTA pH 7.5, 100 M leupeptin. The suspension is frozen and thawed two times in a dry ice-acetone bath using a 600 mL lyophilizing flask, then homogenized in a glass/teflon mortar and pestle and made 1 mM in DIFP. The NaCl concentration is adjusted to 0.5 M with a stock solution of 4 M NaCl. After stirring the suspension at 4°C, it is centrifuged in polycarbonate tubes at 33,000 rpm for 60 minutes at 4°C. The supernatant (0.5 M NaCl wash) is removed and saved; this supernatant contains the soluble form of P-selectin. Care is taken not to remove the top part of the pellet with the supernatant. The pellets are then homogenized in extraction buffer (TBS, 5 mM benzamidine, 5 mM EDTA, pH 7.5, 100  $\mu$ M leupeptin, 2% Triton X-100). After centrifugation at 19,500 rpm for 25 minutes at 4°C, the supernatant is removed. The extraction procedure is repeated with the pellet and the supernatant is combined with the first supernatant. The combined extracts, which contain the membrane form of P-selectin, are adjusted to 0.5 M NaCl.

20 The soluble fraction (0.5 M NaCl wash) and the membrane extract (also adjusted to 0.5 M NaCl) are absorbed with separate pools of the monoclonal antibody S12 (directed to P-selectin) previously coupled to Affigel (Biorad) at 5 mg/mL for 2 hours at 4°C. After letting the resins settle, 25 the supernatants are removed. The S12 Affigel containing bound GMP-140 is then loaded into a column and washed overnight at 4°C with 400 mL of 0.5 M NaCl, 20 mM Tris pH 7.5, 0.01% Lubrol PX.

Bound P-selectin is eluted from the S12 Affigel with 30 100 mL of 80% ethylene glycol, 1 mM MES pH 6.0, 0.01% Lubrol PX. Peak fractions with absorbance at 280 nm are pooled. Eluates are dialyzed against TBS with 0.05% Lubrol, then applied to a Mono Q column (FPLC from Pharmacia). The concentrated protein is step eluted with 2 M NaCl, 20 mM Tris pH 7.5 (plus 0.05% Lubrol PX for the membrane fraction). Peak fractions are dialyzed into TBS pH 7.5 (plus 0.05% Lubrol PX for the membrane fraction).

- 23 -

P-selectin is plated at 5 micrograms/mL and the control proteins: human serum albumin (Alb), platelet glycoprotein IIb/IIIa (IIb), von Willebrand factor (vWF), fibrinogen (FIB), thrombomodulin (TM), gelatin (GEL) or human serum (HS), are added at 50 micrograms/mL. All wells are blocked for 2 hours at 22°C with 300 microliters HBSS containing 10 mg/mL HSA, then washed three times with HBSS containing 0.1% Tween-20 and once with HBSS. Cells ( $2 \times 10^5$  per well) are added to the wells and incubated at 22°C for 20 minutes. The wells are then filled with HBSS/HSA, sealed with acetate tape (Dynatech), and centrifuged inverted at 150 g for 5 minutes. After discarding nonadherent cells and supernates, the contents of each well are solubilized with 200 microliters 0.5% hexadecyltrimethylammonium bromide, Sigma, in 50 mM potassium phosphate, pH. 6.0, and assayed for myeloperoxidase activity, Ley, et al., Blood 73, 1324-1330 (1989). The number of cells bound is derived from a standard curve of myeloperoxidase activity versus numbers of cells. Under all assay conditions, the cells release less than 5% of total myeloperoxidase and lactate dehydrogenase. Inhibition is read as a lower percent adhesion, so that a value of 5% means that 95% of the specific adhesion was inhibited.

Peptides are tested at concentrations between 1.0 mM to 0.001 mM and a percent inhibition calculated for each concentration. A least squares fit is done on a plot of peptide concentration versus percent inhibition and an  $IC_{50}$  value calculated. The  $IC_{50}$  is defined as the concentration of peptide that will inhibit 50% of the neutrophil binding to the P-selectin lawn.

Activity data are presented either as an  $IC_{50}$  for each peptide or the percent inhibition at a defined concentration.

Table I gives the  $IC_{50}$  values in mM for peptides of the invention in inhibiting the binding of human neutrophils to P-selectin.

TABLE I

## INHIBITION OF BINDING OF HUMAN NEUTROPHILS TO P-SELECTIN

	<u>Structure</u>		<u>IC<sub>50</sub> (mM)</u>
5	CLKKKHALCY-NH <sub>2</sub>	SEQ ID NO:1	0.269
	CSKKKLALCY-NH <sub>2</sub>	SEQ ID NO:2	0.048
	CHKLKAALCY-NH <sub>2</sub>	SEQ ID NO:3	0.282
	Cyclo- (CLKKKHALC) -Y-NH <sub>2</sub>	SEQ ID NO:4	0.626
	Cyclo- (CSKKKLALC) -Y-NH <sub>2</sub>	SEQ ID NO:5	0.078
10	Cyclo- (CHKLKAALC) -Y-NH <sub>2</sub>	SEQ ID NO:6	0.002
	Ac-FKKKLALCY-NH <sub>2</sub>	SEQ ID NO:7	0.074
	FKKKLALCY-NH <sub>2</sub>	SEQ ID NO:8	0.020
	Ac-HKKKLALCY-NH <sub>2</sub>	SEQ ID NO:9	0.011
	HKKKLALCY-NH <sub>2</sub>	SEQ ID NO:10	0.055
15	LKKKHALCY-NH <sub>2</sub>	SEQ ID NO:11	0.178
	Ac-LKKKLALCY-NH <sub>2</sub>	SEQ ID NO:12	0.026
	LKKKLALCY-NH <sub>2</sub>	SEQ ID NO:13	0.065
	Ac-NKKKLALCY-NH <sub>2</sub>	SEQ ID NO:14	0.053
	NKKKLALCY-NH <sub>2</sub>	SEQ ID NO:15	0.019
20	PKKKLALCY-NH <sub>2</sub>	SEQ ID NO:16	0.103
	QKKKLALCY-NH <sub>2</sub>	SEQ ID NO:17	1.013
	SHKKLALCY-NH <sub>2</sub>	SEQ ID NO:18	0.362
	Ac-SKAKLALCY-NH <sub>2</sub>	SEQ ID NO:19	0.060
	SKFKLALCY-NH <sub>2</sub>	SEQ ID NO:20	0.037
25	SKHKLALCY-NH <sub>2</sub>	SEQ ID NO:21	0.888
	SKKFLALCY-NH <sub>2</sub>	SEQ ID NO:22	0.554
	Ac-SKKKAALCY-NH <sub>2</sub>	SEQ ID NO:23	0.192
	SKKKAALCY-NH <sub>2</sub>	SEQ ID NO:24	0.232
	SKKKHALCY-NH <sub>2</sub>	SEQ ID NO:25	0.656
30	SKKKIALCY-NH <sub>2</sub>	SEQ ID NO:26	0.062
	SKKKLAFCY-NH <sub>2</sub>	SEQ ID NO:27	0.086
	SKKKLAICY-NH <sub>2</sub>	SEQ ID NO:28	0.107
	SKKKLALCF-NH <sub>2</sub>	SEQ ID NO:29	0.065
	SKKKLALCI-NH <sub>2</sub>	SEQ ID NO:30	0.867
35	SKKKLALCY-NH <sub>2</sub>	SEQ ID NO:31	0.019

- 25 -

	SKKKLALFY-NH <sub>2</sub>	SEQ ID NO:32	0.015
	SKKKLALIV-NH <sub>2</sub>	SEQ ID NO:33	0.390
	Ac-SKKKLALIY-NH <sub>2</sub>	SEQ ID NO:34	0.128
	SKKKLALIY-NH <sub>2</sub>	SEQ ID NO:35	0.043
5	SKKKLALHY-NH <sub>2</sub>	SEQ ID NO:36	0.177
	Ac-SKKKLALLY-NH <sub>2</sub>	SEQ ID NO:37	0.088
	SKKKLALLY-NH <sub>2</sub>	SEQ ID NO:38	0.131
	Ac-SKKKLALVY-NH <sub>2</sub>	SEQ ID NO:39	0.164
	SKKKLALVY-NH <sub>2</sub>	SEQ ID NO:40	0.233
10	SKKKLALTY-NH <sub>2</sub>	SEQ ID NO:41	0.423
	SKKKLAPCY-NH <sub>2</sub>	SEQ ID NO:42	0.897
	SKKKLFLCY-NH <sub>2</sub>	SEQ ID NO:43	0.095
	SKKKLHLCY-NH <sub>2</sub>	SEQ ID NO:44	0.207
	SKKKLILCY-NH <sub>2</sub>	SEQ ID NO:45	0.095
15	SKKKLQACY-NH <sub>2</sub>	SEQ ID NO:46	0.329
	Ac-SKKKTALCY-NH <sub>2</sub>	SEQ ID NO:47	0.082
	SKKQLALCY-NH <sub>2</sub>	SEQ ID NO:48	0.195
	Ac-SKKRLALCY-NH <sub>2</sub>	SEQ ID NO:49	0.009
	SKKRLALCY-NH <sub>2</sub>	SEQ ID NO:50	0.004
20	Ac-SKLKLALCY-NH <sub>2</sub>	SEQ ID NO:51	0.012
	SKLKLALCY-NH <sub>2</sub>	SEQ ID NO:52	0.009
	Ac-SKRKLALCY-NH <sub>2</sub>	SEQ ID NO:53	0.012
	SKRKLALCY-NH <sub>2</sub>	SEQ ID NO:54	0.004
	Ac-SKRKRALCY-NH <sub>2</sub>	SEQ ID NO:55	0.026
25	SKRKRALCY-NH <sub>2</sub>	SEQ ID NO:56	0.024
	Ac-SKRRRLALCY-NH <sub>2</sub>	SEQ ID NO:57	0.008
	SKRRLALCY-NH <sub>2</sub>	SEQ ID NO:58	0.008
	SKRRLALSY-NH <sub>2</sub>	SEQ ID NO:59	0.632
	SKSKLALCY-NH <sub>2</sub>	SEQ ID NO:60	0.858
30	Ac-SRARLALCY-NH <sub>2</sub>	SEQ ID NO:61	0.047
	SRARLALCY-NH <sub>2</sub>	SEQ ID NO:62	0.034
	Ac-SRKKLALCY-NH <sub>2</sub>	SEQ ID NO:63	0.017
	SRKKLALCY-NH <sub>2</sub>	SEQ ID NO:64	0.016
	Ac-SRKRLALCY-NH <sub>2</sub>	SEQ ID NO:65	0.018
35	SRKRLALCY-NH <sub>2</sub>	SEQ ID NO:66	0.003
	SRKRLALSY-NH <sub>2</sub>	SEQ ID NO:67	0.586
	Ac-SRRKLALCY-NH <sub>2</sub>	SEQ ID NO:68	0.027

- 26 -

SRRKLALCY-NH <sub>2</sub>	SEQ ID NO:69	0.014
SSKKLALCY-NH <sub>2</sub>	SEQ ID NO:70	0.282

#### Clinical Applications

Since the selectins have several functions related to 5 leukocyte adherence, inflammation, and coagulation, compounds which interfere with binding of P-selectin, E-selectin or L-selectin can be used to modulate these responses.

For example, the peptides can be used to competitively inhibit leukocyte adherence by competitively binding to P-selectin receptors on the surface of leukocytes. This kind 10 of therapy would be particularly useful in acute situations where effective, but transient, inhibition of leukocyte-mediated inflammation is desirable. Chronic therapy by infusion of the peptides may also be feasible in some 15 circumstances.

An inflammatory response may cause damage to the host if unchecked, because leukocytes release many toxic molecules that can damage normal tissues. These molecules include 20 proteolytic enzymes and free radicals. Examples of pathological situations in which leukocytes can cause tissue damage include injury from ischemia and reperfusion, bacterial sepsis and disseminated intravascular coagulation, adult respiratory distress syndrome, tumor metastasis, rheumatoid arthritis and atherosclerosis.

Reperfusion injury is a major problem in clinical 25 cardiology. Therapeutic agents that reduce leukocyte adherence in ischemic myocardium can significantly enhance the therapeutic efficacy of thrombolytic agents. Thrombolytic therapy with agents such as tissue plasminogen 30 activator or streptokinase can relieve coronary artery obstruction in many patients with severe myocardial ischemia prior to irreversible myocardial cell death. However, many such patients still suffer myocardial neurosis despite restoration of blood flow. This "reperfusion injury" is 35 known to be associated with adherence of leukocytes to vascular endothelium in the ischemic zone, presumably in part

- 27 -

because of activation of platelets and endothelium by thrombin and cytokines that makes them adhesive for leukocytes (Romson et al., Circulation 67: 1016-1023 (1983)). These adherent leukocytes can migrate through the endothelium 5 and destroy ischemic myocardium just as it is being rescued by restoration of blood flow.

There are a number of other common clinical disorders in which ischemia and reperfusion results in organ injury mediated by adherence of leukocytes to vascular surfaces, 10 including strokes; mesenteric and peripheral vascular disease; organ transplantation; and circulatory shock (in this case many organs might be damaged following restoration of blood flow).

Bacterial sepsis and disseminated intravascular 15 coagulation often exist concurrently in critically ill patients. They are associated with generation of thrombin, cytokines, and other inflammatory mediators, activation of platelets and endothelium, and adherence of leukocytes and aggregation of platelets throughout the vascular system. 20 Leukocyte-dependent organ damage is an important feature of these conditions.

Adult respiratory distress syndrome is a devastating pulmonary disorder occurring in patients with sepsis or following trauma, which is associated with widespread 25 adherence and aggregation of leukocytes in the pulmonary circulation. This leads to extravasation of large amounts of plasma into the lungs and destruction of lung tissue, both mediated in large part by leukocyte products.

Two related pulmonary disorders that are often fatal 30 are in immunosuppressed patients undergoing allogeneic bone marrow transplantation and in cancer patients suffering from complications that arise from generalized vascular leakage resulting from treatment with interleukin-2 treated LAK cells (lymphokine-activated lymphocytes). LAK cells are known to 35 adhere to vascular walls and release products that are presumably toxic to endothelium. Although the mechanism by which LAK cells adhere to endothelium is now known, such

cells could potentially release molecules that activate endothelium and then bind to endothelium by mechanisms similar to those operative in neutrophils.

Tumor cells from many malignancies (including 5 carcinomas, lymphomas, and sarcomas) can metastasize to distant sites through the vasculature. The mechanisms for adhesion of tumor cells to endothelium and their subsequent migration are not well understood, but may be similar to those of leukocytes in at least some cases. The association 10 of platelets with metastasizing tumor cells has been well described, suggesting a role for platelets in the spread of some cancers. Recently, it was reported that P-selectin binds to tumor cells in a variety of human carcinoma tissue sections (colon, lung, and breast), and that P-selectin binds 15 to the cell surface of a number of cell lines derived from various carcinomas, but not from melanomas. Aruffo, A., et al., Proc. Natl. Acad. Sci. USA, 89, 2292-2296 (1992). Aruggo et al. also reference earlier work suggesting that E-selectin might be involved in tumor metastasis by mediating 20 the adhesion of a colon carcinoma cell line (HT-20) to activated endothelial cells *in vitro*. Platelet-leukocyte interactions are believed to be important in atherosclerosis. Platelets might have a role in recruitment of monocytes into 25 atherosclerotic plaques; the accumulation of monocytes is known to be one of the earliest detectable events during atherogenesis. Rupture of a fully developed plaque may not only lead to platelet deposition and activation and the promotion of thrombus formation, but also the early recruitment of neutrophils to an area of ischemia.

30 Another area of potential application is in the treatment of rheumatoid arthritis.

The criteria for assessing response to therapeutic modalities employing these peptides, and, hence, effective dosages of the peptides of this invention for treatment, are 35 dictated by the specific condition and will generally follow standard medical practices. For example, the criteria for the effective dosage to prevent extension of myocardial

- 29 -

infarction would be determined by one skilled in the art by looking at marker enzymes of myocardial necrosis in the plasma, by monitoring the electrocardiogram, vital signs, and clinical response. For treatment of acute respiratory distress syndrome, one would examine improvements in arterial oxygen, resolution of pulmonary infiltrates, and clinical improvement as measured by lessened dyspnea and tachypnea. For treatment of patients in shock (low blood pressure), the effective dosage would be based on the clinical response and specific measurements of function of vital organs such as the liver and kidney following restoration of blood pressure. Neurologic function would be monitored in patients with stroke. Specific tests are used to monitor the functioning of transplanted organs; for example, serum creatinine, urine flow, and serum electrolytes in patients undergoing kidney transplantation.

#### Diagnostic Reagents

The peptides can also be used for the detection of human disorders in which the ligands for the selectins might be defective. Such disorders would most likely be seen in patients with increased susceptibility to infections in which leukocytes might not be able to bind to activated platelets or endothelium. Cells to be tested, usually leukocytes, are collected by standard medically approved techniques and screened. Detection systems include ELISA procedures, binding of radiolabeled antibody to immobilized activated cells, flow cytometry, or other methods known to those skilled in the art. Inhibition of binding in the presence and absence of the lectin domain peptides can be used to detect defects or alterations in selectin binding. For selectins, such disorders would most likely be seen in patients with increased susceptibility to infections in which leukocytes would have defective binding to platelets and endothelium because of deficient leukocyte ligands for P-selectin.

The peptide is labeled radioactively, with a fluorescent tag, enzymatically, or with electron dense material such as gold for electron microscopy. The cells to be examined, usually leukocytes, are incubated with the 5 labeled peptides and binding assessed by methods described above with antibodies to P-selectin, or by other methods known to those skilled in the art. If ligands for P-, E- or L-selectin are also found in the plasma, they can also be measured with standard ELISA or radioimmunoassay procedures, 10 using labeled P-, E- or L-selectin-derived peptide instead of antibody as the detecting reagent.

The peptides can also be useful in *in vivo* imaging of concentrations of cells bearing selectin ligands. Cells expressing selectin ligands whose abnormally high local 15 concentrations or presence within the body such as cancer cells, is indicative of a disorder can be imaged using labeled peptides. These labels may be either intrinsic or extrinsic to the structure of the specific selectin peptide and may include, but not be limited to high energy emitters 20 such as  $^{111}\text{In}$  or non-radioactive dense atoms to enhance x-ray contrast.

The following examples are presented to illustrate, not limit, the invention. In the examples and throughout the specification, parts are by weight unless otherwise 25 indicated.

**EXAMPLE I: Cyclo-(cystinyl-leucyl-lysyl-lysyl-lysyl-histidyl-alanyl-leucyl-cystinyl)-tyrosine-amide**

The peptide was prepared on an ABI Model 431A Peptide Synthesizer using Version 1.12 of the standard BOC software. 30 4-methyl benzhydrylamine resin (0.625 g, 0.5 mmol) was used in the synthesis. The final weight of the resin was 1.84 g.

The peptide was cleaved from the resin (1.8 g) using 18 mL of HF and 1.8 mL of anisole for 60 min at 0°C. The resin was washed with ether and the peptide extracted with 35 TFA/DCM (1:1, v/v) (3 x 15 mL) to give 720 mg of crude peptide. The crude linear peptide (500 mg) was dissolved in 80 mL of 50% HOAc and then added dropwise to the mixture of

- 31 -

water (1200 mL), NH<sub>4</sub>OH (to keep pH approx. 7.5) and 0.01 M K<sub>3</sub>Fe(CN)<sub>6</sub> (approx. 3 mL). After each addition of the linear precursor to the reaction mixture (approx. 1.5 mL) the pH was adjusted to 7.5 by addition of NH<sub>4</sub>OH followed by addition of 5 more K<sub>3</sub>Fe(CN)<sub>6</sub> solution. The total volume of the 0.01 M K<sub>3</sub>Fe(CN)<sub>6</sub> solution used for oxidation was 40 mL. An additional 2 mL of K<sub>3</sub>Fe(CN)<sub>6</sub> solution was added extra and the mixture was stirred over 20 min (pH = 7.5), then the pH was adjusted to 4-5 by addition of HOAc followed by stirring with 10 5 g of anion exchange AG 3-X4, 200-400 mesh, free base form (Bio-Rad) over 30 min. The resin was filtered off, washed with 5% acetic acid (3 x 100 mL) and combined fractions (approx. 1700 mL) were loaded onto a Vydac C-18 column (15 $\mu$ , 10 X 30 cm) eluting with 0-15% over 5 min and a 15-55% 15 gradient of 80% ethanol in 0.1% TFA over 55 min at a flow rate of 120 mL per min. Fractions were collected, analyzed by HPLC and pure fractions pooled, evaporated to approx. 100 mL and lyophilized to give 146 mg of white solids. Amino acid analysis: Ala 1.01 (1), Cys 1.60 (2), His 1.03 (1), Leu 20 2.00 (2), Lys 2.96 (3), Tyr 0.72 (1).

**EXAMPLE II:** Cyclo-(cystinyl-histidyl-lysyl-leucyl-lysyl-alanyl-alanyl-leucyl-cystinyl)-tyrosine-amide

The peptide was prepared on an ABI Model 431A Peptide 25 Synthesizer using Version 1.12 of the standard BOC software. 4-methyl benzhydrylamine resin (0.625 g, 0.5 mmol) was used in the synthesis. The final weight of the resin was 1.66 g.

The peptide was cleaved from the resin (1.6 g) using 16 mL of HF and 1.6 mL of anisole for 60 min at 0°C. The 30 resin was washed with ether and the peptide extracted with TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1, v/v) (3 x 15 mL) to give 748 mg of crude peptide. The crude linear peptide (500 mg) was dissolved in 65 mL of 70% HOAc and then added dropwise to the mixture of water (1200 mL), NH<sub>4</sub>OH (to keep pH approx. 7.5) and 0.01 M 35 K<sub>3</sub>Fe(CN)<sub>6</sub> (approx. 3 mL). After each addition of the linear precursor to the reaction mixture (approx. 1.5 mL) the pH was adjusted to 7.5 by addition of NH<sub>4</sub>OH followed by addition of

more  $K_3Fe(CN)_6$  solution. The total volume of the 0.01 M  $K_3Fe(CN)_6$  solution used for oxidation was 30 mL. An additional 2 mL of  $K_3Fe(CN)_6$  solution was added extra and the mixture was stirred over 20 min (pH = 7.5), then the pH was 5 adjusted to 4-5 by addition of HOAc followed by stirring with 5 g of anion exchange AG 3-X4, 200-400 mesh, free base form (Bio-Rad) over 30 min. The resin was filtered off, washed with 5% acetic acid (3 x 100 mL) and combined fractions (approx. 1700 mL) were loaded onto a Vydac C-18 column (15  $\mu$ , 10 x 30 cm) eluting with a 0-15% over 5 min and 15-55% gradient of 80% ethanol in 0.1% TFA over 55 min at a flow rate of 120 mL per min. Fractions were collected, analyzed by HPLC and pure fractions pooled and lyophilized to give 86 mg of white solid. Amino acid analysis: Ala 2.00 (2), Cys 15 1.55 (2), His 1.00 (1), Leu 2.01 (2), Lys 1.98 (2), Tyr 0.70 (1). Ellman's test for quantitative determination of SH was negative.

EXAMPLE III: Cystinyl-leucyl-lysyl-lysyl-histidyl-  
20 alanyl-leucyl-cystinyl-tyrosine-amide

The peptide was prepared on an ABI Model 431A Peptide Synthesizer using Version 1.12 of the standard BOC software. 4-methyl benzhydrylamine resin (0.625 g, 0.5 mmol) was used in the synthesis. The final weight of the resin was 1.84 g. 25 The peptide was cleaved from the resin (1.8 g) using 18 mL of HF and 1.8 mL of anisole for 60 min at 0°C. The resin was washed with ether and the peptide extracted with TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1, v/v) (3 x 15 mL) to give 720 mg of crude peptide. 30 The crude peptide (220 mg) was purified on a Vydac C-18 column (15 $\mu$ , 5 x 25 cm) eluting with a 15-45% gradient of 80% acetonitrile in 0.1% TFA over 120 min at a flow rate of 15 mL per min. Fractions were collected, analyzed by HPLC and pure fractions pooled and lyophilized to give 32 mg of 35 white solid. Amino acid analysis: Ala 1.02 (1), Cys 0.88 (2), His 1.06 (1), Leu 1.98 (2), Lys 2.94 (3), Tyr 0.87 (1).

- 33 -

**EXAMPLE IV:** *Cystinyl-histidyl-lysyl-leucyl-lysyl-alanyl-alanyl-leucyl-cystinyl-tyrosine-amide*

The peptide was prepared on an ABI Model 431A Peptide Synthesizer using Version 1.12 of the standard BOC software. 4-methyl benzhydrylamine resin (0.625 g, 0.5 mmol) was used in the synthesis. The final weight of the resin was 1.66 g.

The peptide was cleaved from the resin (1.6 g) using 16 mL of HF and 1.6 mL of anisole for 60 min at 0°C. The resin was washed with ether and the peptide extracted with TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1 v/v) (3 x 15 mL) to give 748 mg of crude peptide.

The crude peptide (249 mg) was purified in two runs on a Vydac C-18 column (15μ, 5 x 25cm) eluting with a 5-45% gradient of 80% acetonitrile in 0.1% TFA over 120 min at a flow rate of 15 mL per min. Fractions were collected, analyzed by HPLC and pure fractions pooled and lyophilized to give 53 mg of white solid. Amino acid analysis: Ala 1.97 (2), Cys 0.91, (2), His 1.10 (1), Leu 1.98 (2), Lys 1.95 (2), Tyr 0.74 (1).

**EXAMPLE V: Cyclo-(cystinyl-serinyl-lysyl-lysyl-lysyl-leucyl-alanyl-leucyl-cystinyl-tyrosine-amide)**

The peptide was prepared on an ABI Model 431A Peptide Synthesizer using Version 1.12 of the standard BOC software. 4-methyl benzhydrylamine resin (0.625 g, 0.5 mmol) was used in the synthesis. The final weight of the resin was 1.61 g.

The peptide was cleaved from the resin (1.6 g) using 16 mL of HF and 1.6 mL of anisole for 60 min at 0°C. The resin was washed with ether and the peptide extracted with TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1, v/v) (3 x 15 mL) to give 680 mg of crude peptide.

The crude linear peptide (460 mg) was dissolved in 60 mL of 50% HOAc and then added dropwise to the mixture of water (1200 mL), NH<sub>4</sub>OH (to keep pH approximately 7.5) and 0.01 M K<sub>3</sub>Fe(CN)<sub>6</sub> (approximately 3 mL). After each addition of the linear precursor to the reaction mixture (approximately 1.5 mL) its pH was adjusted to 7.5 by addition

- 34 -

of NH<sub>4</sub>OH followed by addition of K<sub>3</sub>Fe(CN)<sub>6</sub> solution. The total volume of the 0.01 M K<sub>3</sub>Fe(CN)<sub>6</sub> solution used for oxidation was 37 mL. The additional 2 mL of K<sub>3</sub>Fe(CN)<sub>6</sub> solution was added extra and the mixture was stirred over 20 min (pH = 7.5), then the pH was adjusted to 4-5 by addition of HOAc followed by stirring with 5 g of anion exchange AG 3-X4, 200-400 mesh, free base form (Bio-Rad) over 30 min. The resin was filtered off, washed with 5% acetic acid (3 x 100 mL) and combined fractions (approximately 1650 mL) were loaded onto a Vydac C-18 column (15 $\mu$ , 10 x 30 cm) eluting with a 0-25% over 5 min and 25-55% gradient of 80% ethanol in 0.1% TFA over 55 min at a flow rate of 120 mL per min. Fractions were collected, analyzed by HPLC and pure fractions pooled, evaporated (approximately 100 mL) and lyophilized to give 158 mg of white solid. Amino acid analysis: Ala 1.02 (1), Cys 1.67 (2), Leu 1.99 (2), Lys 2.92 (3), Ser 0.77 (1), Tyr 0.78 (1).

**EXAMPLE VI:** Cystinyl-serinyl-lysyl-lysyl-lysyl-leucyl-alanyl-leucyl-cystinyl-tyrosine-amide

20

The peptide was prepared on an ABI Model 431A Peptide Synthesizer using Version 1.12 of the standard BOC software. 4-methyl benzhydrylamine resin (0.625 g, 0.5 mmol) was used in the synthesis. The final weight of the resin was 1.61 g.

25

The peptide was cleaved from the resin (1.6 g) using 16 mL of HF and 1.6 mL of anisole for 60 min at 0°C. The resin was washed with ether and the peptide extracted with TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1, v/v) (3 x 15 mL) to give 680 mg of crude peptide.

30

The crude peptide (220 mg) was purified on a Vydac C-18 column (15 $\mu$ , 10 x 30 cm) eluting with a 0-30% over 5 min and 30-60% gradient of 80% ethanol in 0.1% TFA over 50 min at a flow rate of 120 mL per min. Fractions were collected, analyzed by HPLC and semi-pure fractions pooled, evaporated (approximately 100 mL) and lyophilized to give 66 mg of semi-pure product.

- 35 -

The semi-pure peptide (66 mg) was repurified on a Vydac C-18 column (15 $\mu$ , 5 x 25 cm) eluting with a 20-50% gradient of 80% acetonitrile in 0.1% TFA over 120 min at a flow rate of 15 mL/min. Fractions were collected, analyzed by HPLC and pure fractions pooled and lyophilized to give 25 mg of white solid.

Amino acid analysis: Ala 1.00 (1), Cys 1.71 (2), Leu 2.00 (2), Lys 3.00 (3), Ser 0.72 (1), Tyr 0.75 (1).

- 36 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Heavner, George A.  
Kruszynski, Marian

5 (ii) TITLE OF INVENTION: PEPTIDE INHIBITORS OF SELECTIN  
BINDING

(iii) NUMBER OF SEQUENCES: 6

10 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz  
and Norris

(B) STREET: One Liberty Place - 46th Floor

(C) CITY: Philadelphia

(D) STATE: PA

(E) COUNTRY: USA

15 (F) ZIP: 19103

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

20 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

25 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Elderkin, Dianne B.

(B) REGISTRATION NUMBER: 28,598

(C) REFERENCE/DOCKET NUMBER: CCOR-0030

30 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 215-568-3100

(B) TELEFAX: 215-568-3439

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- 37 -

(A) NAME/KEY: Peptide  
(B) LOCATION: 10  
(D) OTHER INFORMATION: /label= AMINO MODIFIED  
5 /note= "NH2 ATTACHED TO TERMINAL CARBOXYL  
CARBON"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Cys Leu Lys Lys Lys His Ala Leu Cys Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:2:

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide  
(B) LOCATION: 10  
(D) OTHER INFORMATION: /label= AMINO MODIFIED  
20 /note= "NH2 ATTACHED TO TERMINAL CARBOXYL  
CARBON"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Cys Leu Lys Lys Lys His Ala Leu Cys Tyr  
1 5 10

25 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide  
(B) LOCATION: 10  
35 (D) OTHER INFORMATION: /label= AMINO MODIFIED  
/note= "NH2 ATTACHED TO TERMINAL CARBOXYL  
CARBON"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

- 38 -

Cys Ser Lys Lys Leu Ala Leu Cys Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:4:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

10 (ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 10
- (D) OTHER INFORMATION: /label= AMINO MODIFIED  
/note= "NH2 ATTACHED TO TERMINAL CARBOXYL  
CARBON"

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Cys His Lys Leu Lys Ala Ala Leu Cys Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:5:

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: peptide

30 (ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 10
- (D) OTHER INFORMATION: /label= AMINO MODIFIED  
/note= "NH2 ATTACHED TO TERMINAL CARBOXYL  
CARBON"

30

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1..9
- (D) OTHER INFORMATION: /label= CYCLO-PEPTIDE  
/note= "RESIDUES 1 THROUGH 9 FORM RING"

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Cys Leu Lys Lys Lys His Ala Leu Cys Tyr  
1 5 10

- 39 -

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 10
- (D) OTHER INFORMATION: /label= AMINO MODIFIED  
/note= "NH2 ATTACHED TO TERMINAL CARBOXYL  
CARBON"

(ix) FEATURE:



- (A) NAME/KEY: Peptide
- (B) LOCATION: 1..9
- (D) OTHER INFORMATION: /label= CYCLO-PEPTIDE  
/note= "RESIDUES 1 THROUGH 9 FORM RING"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

20 Cys Ser Lys Lys Lys Leu Ala Leu Cys Tyr  
1 5 10

WHAT IS CLAIMED IS:

## 1. A peptide of Formula I or II:



or pharmaceutically acceptable salts thereof, wherein:

10  $X'$  is an N-terminus amino acid linear sequence of from zero to 10 amino acids, and  $R^1$  is a moiety attached to the terminal  $\alpha$  amino group of  $X'$ , or the terminal  $\alpha$ -amino group of the adjacent amino acid if  $X$  is zero;

15  $X''$  is a C-terminus amino acid linear sequence of from zero to 10 amino acids, and  $R^2$  is a moiety attached to the carboxyl carbon of  $X''$  or the carboxyl carbon of the adjacent amino acid if  $X''$  is zero;

$A'$  is selected from the group consisting of null (signifying no amino acid) and D- or L-cysteine;

20  $A''$  is selected from the group consisting of D- and L-cysteine;

$B'$  is selected from the group consisting of D- or L-histidine, D- or L-serine, D- or L-leucine, D- or L-phenylalanine, D- or L-asparagine, D- or L-proline, and D- or L-glutamine;

25  $C'$  is selected from the group consisting of D- or L-lysine, D- or L-histidine, D- or L-arginine, and D- or L-serine;

30  $D'$  is selected from the group consisting of D- or L-lysine, D- or L-leucine, D- or L-alanine, D- or L-phenylalanine, D- or L-histidine, D- or L-arginine, and D- or L-serine;

$E'$  is selected from the group consisting of D- or L-lysine, D- or L-phenylalanine, D- or L-glutamine, and D- or L-arginine;

35  $F'$  is selected from the group consisting of D- or L-histidine, D- or L-leucine, D- or L-alanine, D- or L-isoleucine, D- or L-threonine, and D- or L-arginine;

- 41 -

G' is selected from the group consisting of D- or L-alanine, D- or L-phenylalanine, D- or L-histidine, D- or L-isoleucine, and D- or L-glutamine;

5 H' is selected from the group consisting of D- or L-leucine, D- or L-phenylalanine, D- or L-isoleucine, D- or L-proline, and D- or L-alanine;

I' is selected from the group consisting of D- or L-cysteine, D- or L-phenylalanine, D- or L-isoleucine, D- or L-histidine, D- or L-leucine, D- or L-valine, D- or L-threonine, and D- or L-serine;

I" is selected from the group consisting of D- and L-cysteine;

J' is selected from the group consisting of D- or L-tyrosine, D- or L-phenylalanine, D- or L-isoleucine, and D- or L-valine;

R<sup>1</sup> is selected from the group consisting of hydrogen (signifying a free N-terminal group), lower alkyl, aryl, formyl, alkanoyl, aroyl, alkyloxycarbonyl or aryloxycarbonyl;

20 R<sup>2</sup> is selected from the group consisting of OH (signifying a free C-terminal carboxylic acid), OR<sup>3</sup>, signifying ester, where R<sup>3</sup> is selected from the group consisting of lower alkyl and aryl; and NR<sup>5</sup>R<sup>6</sup> where R<sup>5</sup> and R<sup>6</sup> are each selected independently from hydrogen, lower alkyl, aryl or cyclic alkyl;

25 and pharmaceutically acceptable salts thereof.

2. The peptide of Claim 1 wherein R<sup>1</sup> is selected from the group consisting of hydrogen and acetyl.

30 3. The peptide of Claim 1 wherein R<sup>2</sup> is selected from the group consisting of OH and NH<sub>2</sub>.

4. The peptide of Claim 3 wherein R<sup>2</sup> is NH<sub>2</sub>.

5. A peptide of Claim 1 having Formula I.

- 42 -

6. A peptide of Claim 5 where R<sup>1</sup> is selected from the group consisting of hydrogen and acetyl and R<sup>2</sup> is selected from the group consisting of OH and NH<sub>2</sub>.

7. A peptide of Claim 6 wherein R<sup>2</sup> is NH<sub>2</sub>.

5 8. A peptide of Claim 5 wherein, independently, A' is null; B' is selected from the group consisting of Phe, His, Leu, Asn and Ser; C' is selected from the group consisting of Lys and Arg; D' is selected from the group consisting of Lys, Phe, Leu, and Ala; E' is selected from the group consisting of Lys and Arg; F' is selected from the group consisting of Leu and Arg; G' is Ala; H' is Leu; I' is selected from the group consisting of Cys, Ile and Phe; and J' is Tyr.

10 9. A peptide of Claim 8 wherein R<sup>2</sup> is NH<sub>2</sub>.

15 10. A peptide of Claim 1 where E' is Arg.

11. A peptide of Claim 9 where E' is Arg.

12. A peptide of Claim 1 having Formula II.

13. A peptide of Claim 12 where R<sup>1</sup> is selected from the group consisting of hydrogen and acetyl and R<sup>2</sup> is selected from the group consisting of OH and NH<sub>2</sub>.

20 14. A peptide of Claim 13 wherein R<sup>2</sup> is NH<sub>2</sub>.

15. A biologically active peptide of Claim 1 selected from the group comprising:

25 (SEQ ID NO:1) Cys-Leu-Lys-Lys-Lys-His-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:2) Cys-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:3) Cys-His-Lys-Leu-Lys-Ala-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

- 43 -

(SEQ ID NO:4) cyclo-(Cys-Leu-Lys-Lys-Lys-His-Ala-Leu-Cys)-Tyr-NH<sub>2</sub>;

5 (SEQ ID NO:5) cyclo-(Cys-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys)-Tyr-NH<sub>2</sub>;  
and

(SEQ ID NO:6) cyclo-(Cys-His-Lys-Leu-Lys-Ala-Ala-Leu-Cys)-Tyr-NH<sub>2</sub>;

(SEQ ID NO:7) Ac-Phe-Lys-Lys-Lys-Leu-Ala-Ley-Cys-Tyr-NH<sub>2</sub>;

10 (SEQ ID NO:8) Phe-Lys-Lys-Lys-Leu-Ala-Ley-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:9) Ac-His-Lys-Lys-Lys-Leu-Ala-Ley-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:10) His-Lys-Lys-Lys-Leu-Ala-Ley-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:11) Leu-Lys-Lys-His-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

15 (SEQ ID NO:12) Ac-Leu-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:13) Leu-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:14) Ac-Asn-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

20 (SEQ ID NO:15) Asn-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:16) Pro-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:17) Gln-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:18) Ser-His-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

25 (SEQ ID NO:19) Ac-Ser-Lys-Ala-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:20) Ser-Lys-Phe-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:21) Ser-Lys-His-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:22) Ser-Lys-Lys-Phe-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

30 (SEQ ID NO:23) Ac-Ser-Lys-Lys-Lys-Ala-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:24) Ser-Lys-Lys-Lys-Ala-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:25) Ser-Lys-Lys-His-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:26) Ser-Lys-Lys-Lys-Ile-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

- 44 -

(SEQ ID NO:27) Ser-Lys-Lys-Lys-Leu-Ala-Phe-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:28) Ser-Lys-Lys-Lys-Leu-Ala-Ile-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:29) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Phe-NH<sub>2</sub>;  
(SEQ ID NO:30) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Ile-NH<sub>2</sub>;  
5 (SEQ ID NO:31) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:32) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Phe-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:33) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Ile-Val-NH<sub>2</sub>;  
(SEQ ID NO:34) Ac-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Ile-Tyr-NH<sub>2</sub>;  
10 (SEQ ID NO:35) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Ile-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:36) Ser-Lys-Lys-Lys-Leu-Ala-Leu-His-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:37) Ac-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Leu-Tyr-NH<sub>2</sub>;  
15 (SEQ ID NO:38) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Leu-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:39) Ac-Ser-Lys-Lys-Lys-Leu-Ala-Leu-Val-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:40) Ser-Lys-Lys-Lys-Leu-Ala-Leu-Val-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:41) Ser-Lys-Lys-Lys-Leu-Ala-Ley-Thr-Tyr-NH<sub>2</sub>;  
20 (SEQ ID NO:42) Ser-Lys-Lys-Lys-Leu-Ala-Pro-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:43) Ser-Lys-Lys-Lys-Leu-Phe-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:44) Ser-Lys-Lys-Lys-Leu-His-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:45) Ser-Lys-Lys-Lys-Leu-Ile-Leu-Cys-Tyr-NH<sub>2</sub>;  
25 (SEQ ID NO:46) Ser-Lys-Lys-Lys-Leu-Gln-Ala-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:47) Ac-Ser-Lys-Lys-Lys-thr-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:48) Ser-Lys-Lys-Gln-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:49) Ac-Ser-Lys-Lys-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
30 (SEQ ID NO:50) Ser-Lys-Lys-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;  
(SEQ ID NO:51) Ac-Ser-Lys-Leu-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

- 45 -

(SEQ ID NO:52) Ser-Lys-Leu-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:53) Ac-Ser-Lys-Arg-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:54) Ser-Lys-Arg-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

5 (SEQ ID NO:55) Ac-Ser-Lys-Arg-Lys-Arg-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:56) Ser-Lys-Arg-Lys-Arg-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:57) Ac-Ser-Lys-Arg-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

10 (SEQ ID NO:58) Ser-Lys-Arg-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:59) Ser-Lys-Arg-Arg-Leu-Ala-Leu-Ser-Tyr-NH<sub>2</sub>;

(SEQ ID NO:60) Ser-Lys-Ser-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:61) Ac-Ser-Arg-Ala-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

15 (SEQ ID NO:62) Ser-Arg-Ala-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:63) Ac-Ser-Arg-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:64) Ser-Arg-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

20 (SEQ ID NO:65) Ac-Ser-Arg-Lys-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:66) Ser-Arg-Lys-Arg-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:67) Ser-Arg-Lys-Arg-Leu-Ala-Leu-Ser-Tyr-NH<sub>2</sub>;

(SEQ ID NO:68) Ac-Ser-Arg-Arg-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

25 (SEQ ID NO:69) Ser-Arg-Arg-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

(SEQ ID NO:70) Ser-Ser-Lys-Lys-Leu-Ala-Leu-Cys-Tyr-NH<sub>2</sub>;

16. A pharmaceutical composition comprising at least one peptide of claim 1 in an amount effective to inhibit cellular adherence and a pharmaceutically acceptable carrier or diluent.

- 46 -

17. A method for inhibiting leukocyte adherence in a host comprising the step of administering to said host at least one peptide of Claim 1 in an amount effective to inhibit leukocyte adherence.

5 18. A method for modifying binding of a selectin in a host comprising administering to said host at least one peptide of Claim 1 in an amount effective to inhibit cellular adherence.

10 19. The method of Claim 16 wherein said selectin is selected from the group consisting of P-selectin, E-selectin and L-selectin.

20. A method for decreasing inflammation in a host comprising administering to said host at least one peptide of claim 1 in an amount effective to decrease inflammation.

15 21. A method for decreasing coagulation in a host comprising administering to said host at least one peptide of claim 1 in an amount effective to decrease coagulation.

20 22. A method for treating a host having a condition selected from the group consisting of ischemia and reperfusion, bacterial sepsis and disseminated intravascular coagulation, adult respiratory distress syndrome, tumor metastasis, rheumatoid arthritis and atherosclerosis, comprising administering to said host at least one biologically active peptide of claim 1 in an amount effective to treat said condition.

25 23. A method of detecting defective selectin-binding ligands and/or defective integrin-binding ligands in a host comprising the steps of:

30 (a) taking a sample of the cells to be tested from said host;

- 47 -

(b) contacting said cells to be tested with a labeled peptide of Claim 1; and

(c) assessing the binding of said labeled peptide to said cell to be tested.

5 24. The method of Claim 23 wherein said cells to be tested are leukocytes.

10 25. A method of detecting high concentrations or elevated localized concentrations of selectin binding cells and/or integrin binding cells in a host comprising the steps of:

(a) administering to said host a labeled peptide of Claim 1;

(b) withdrawing a sample of cells from said host; and

15 (c) assessing the binding of said labeled peptide to said sample of cells.

26. The method of Claim 25 wherein said cells are leukocytes.

20 27. The method of Claim 25 wherein said cells are tumor cells.

25 28. The method of Claim 25 wherein said peptide is labeled with a moiety selected from the group comprising radioactive tracers, fluorescent tags, enzymes, and electron-dense materials.

29. A method of preparing a peptide of Claim 1 comprising adding amino acids either singly or in pre-formed blocks of amino acids to an appropriately functionalized solid support.

30 30. A method of preparing a peptide of Claim 1 comprising adding amino acids either singly or in preformed

- 48 -

blocks in solution or suspension by chemical ligation techniques.

31. A method of preparing a peptide of Claim 1 comprising adding amino acids either singly or in preformed 5 blocks in solution or suspension by enzymatic ligation techniques.

32. A method of preparing a peptide of Claim 1 comprising enzymatically by inserting nucleic acids encoding the peptide into an expression vector, expressing 10 the DNA, and translating the DNA into the peptide.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/12110

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C07K 1/02, 1/04, 7/06, 7/10, 7/64; C12P 21/02; A61K 37/02  
US CL :514/9, 15; 530/317, 328, 334, 338, 339; 435/68.1; 930/21, 260

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/9, 15; 530/317, 328, 334, 338, 339; 435/68.1; 930/21, 260

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, BIOSIS, CA, INPADOC, JICST-E, MEDLINE search terms: selectin, fragment, peptide, ligand, binding

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US, A, 5,192,746 (Lobl et al) 09 March 1993, col. 6, line 51 - col. 7, line 12.	1-22, 29-31
A,P	US, A, 5,198,424 (McEver) 30 March 1993, col. 11, lines 2-50.	1-22, 29-31

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be part of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 January 1994

Date of mailing of the international search report

FEB 25 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

STEPHEN WALSH

*D. Kegea Jr*

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/12110

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

(Telephone Practice)

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-22, 29-31

Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US93/12110

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-22 and 29-31, drawn to peptides, pharmaceutical compositions, methods of treatment and methods of solid and liquid phase peptide synthesis, classified in Class 514, subclass 12.

Group II, claims 23 and 24, drawn to an in vitro method for detecting defective selectin-binding ligands, classified in Class 435, subclass 7.1.

Group III, claims 25-28, drawn to an in vivo diagnostic method, classified in Class 424, subclass 9.

Group IV, claim 32, drawn to a recombinant method of peptide synthesis, classified in Class 435, subclass 69.1.

The inventions listed as Groups I-IV do not meet the requirements for Unity of Invention for the following reasons: The Groups are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept. Specifically, the groups are directed to different methods practiced with materially different process steps for materially different purposes. Note that PCT Rule 13 does not provide for multiple methods within a single application.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**